stockrowCollegium Pharmaceutical, Inc. (COLL) vs Evolus, Inc. (EOLS)
- Collegium Pharmaceutical, Inc. COLL 25.07 +5.91%
- Evolus, Inc. EOLS 6.86 −8.17%
Collegium Pharmaceutical, Inc. and Evolus, Inc. are both Drug Manufacturers Specialty & Generic companies. Collegium Pharmaceutical, Inc. is the larger, with a market value of $819.1M against $448.8M — 1.8× the size. Evolus, Inc. has negative trailing earnings, so its P/E is not meaningful; Collegium Pharmaceutical, Inc. trades at 20.5×. Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against 7.68%. Collegium Pharmaceutical, Inc. has the higher net margin (4.68% vs −9.56%) and the higher return on invested capital (5.63% vs −12.6%). Across the 18 metrics below, Evolus, Inc. leads on 10 and Collegium Pharmaceutical, Inc. on 8.
Valuation
Profitability
| Metric | COLL | EOLS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 59.05% | 66.38% | 53.51% |
| Operating margin | 15.22% | (4.79%) | 0.00% |
| Net margin | 4.68% | (9.56%) | (2.45%) |
| Free cash flow margin | 41.25% | (2.71%) | 0.00% |
| Return on equity | 13.36% | 93.47% | (0.80%) |
| Return on assets | 2.06% | (12.38%) | (1.67%) |
| Return on invested capital | 5.63% | (12.60%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack